| Year |
Citation |
Score |
| 2019 |
Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, ... ... Lin WC, et al. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature Communications. 10: 5114. PMID 31704972 DOI: 10.1038/s41467-019-13105-5 |
0.365 |
|
| 2017 |
Rajbhandari N, Lin WC, Wehde BL, Triplett AA, Wagner KU. Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers. Cell Reports. 18: 2243-2255. PMID 28249168 DOI: 10.1016/j.celrep.2017.02.013 |
0.681 |
|
| 2016 |
Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. PMID 26779812 DOI: 10.1038/Nm.4032 |
0.362 |
|
| 2015 |
Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nature Communications. 6: 6744. PMID 25855536 DOI: 10.1038/ncomms7744 |
0.553 |
|
| 2014 |
Lin WC, Rajbhandari N, Wagner KU. Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies. Cancer Research. 74: 2138-43. PMID 24670819 DOI: 10.1158/0008-5472.CAN-13-3437 |
0.662 |
|
| 2013 |
Lin WC, Schmidt JW, Creamer BA, Triplett AA, Wagner KU. Gain-of-function of Stat5 leads to excessive granulopoiesis and lethal extravasation of granulocytes to the lung. Plos One. 8: e60902. PMID 23565285 DOI: 10.1371/Journal.Pone.0060902 |
0.678 |
|
| 2013 |
Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Research. 73: 1821-30. PMID 23467612 DOI: 10.1158/0008-5472.Can-12-2067 |
0.695 |
|
| 2012 |
Lin W, Rajbhandari N, Liu C, Sakamoto K, Batra S, Opavsky R, Felsher D, Hollingsworth M, Hebrok M, Rui H, Wagner K. Abstract LB-429: Dormant cancer cells contribute to residual disease in a mouse model for reversible pancreatic cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-429 |
0.694 |
|
| 2011 |
Zhang Q, Sakamoto K, Liu C, Triplett AA, Lin WC, Rui H, Wagner KU. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Research. 71: 7513-24. PMID 22037875 DOI: 10.1158/0008-5472.Can-11-1783 |
0.652 |
|
| 2011 |
Lin W, Zhang Q, Opavsky R, DiMaio DJ, Felsher DW, Batra SK, Hollingsworth MA, Wagner K. Abstract 2384: A novel mouse model for the study of c-MYC during initiation and progression of pancreatic ductal adenocarcinoma Cancer Research. 71: 2384-2384. DOI: 10.1158/1538-7445.Am2011-2384 |
0.696 |
|
| 2011 |
Zhang Q, Sakamoto K, Triplett AA, Lin W, Creamer BA, Wagner K. Abstract 2379: Cyclin D3 is important for ErbB2-induced mammary cancer initiation and progression in the absence of Cyclin D1 Cancer Research. 71: 2379-2379. DOI: 10.1158/1538-7445.Am2011-2379 |
0.686 |
|
| 2010 |
Zhang Q, Triplett AA, Harms DW, Lin WC, Creamer BA, Rizzino A, Wagner KU. Temporally and spatially controlled expression of transgenes in embryonic and adult tissues. Transgenic Research. 19: 499-509. PMID 19821046 DOI: 10.1007/S11248-009-9329-1 |
0.673 |
|
| 2009 |
Sakamoto K, Lin WC, Triplett AA, Wagner KU. Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy. Cancer Research. 69: 6642-50. PMID 19638583 DOI: 10.1158/0008-5472.CAN-09-0746 |
0.715 |
|
| Show low-probability matches. |